Core Insights - Euronext announced the results of the annual review for the PSI® index, effective from December 22, 2025, with no changes in the index composition for the December 2025 quarterly review [1][2]. Company Overview - Euronext operates as a leading European capital market infrastructure, covering the entire capital markets value chain, including listing, trading, clearing, settlement, and custody [4]. - As of September 2025, Euronext's regulated exchanges host over 1,700 listed issuers with a total market capitalization of €6.5 trillion, making it a significant player in European equity trading, handling 25% of European lit equity trading [5]. Recent Developments - In November 2025, Euronext successfully acquired a majority stake in the Athens Stock Exchange (ATHEX), enhancing its pan-European market infrastructure [6].

Core Insights - EssilorLuxottica is collaborating with Fondazione Chips-IT to enhance its leadership in smart eyewear through advanced chip development [2][3] - The partnership aims to leverage open-source hardware to accelerate research and development in ultra-low-power electronics and wearable computing [3][4] Company Overview - EssilorLuxottica has invested significantly in platforms and technologies to create foundational components for smart eyewear, focusing on seamless user experiences [4] - The company is committed to reimagining the electronics in smart eyewear to meet industry-specific needs [4] Industry Context - Fondazione Chips-IT is a key player in the Italian semiconductor ecosystem, focusing on integrated circuit design and fostering collaborations to enhance global competitiveness [5] - The foundation's mission includes optimizing electronic design automation workflows and exploring next-generation chip architectures [5]

Le 10 décembre 2025 Information relative au nombre total de droits de vote et d’actions composant le capital social Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : Euronext Paris Compartiment : Compartiment ACode ISIN : FR0000054470Site web : www.ubisoftgroup.com Information mensuelle au 30 novembre 2025(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers) DateNombre total d’actions composant le capital ...

Core Viewpoint - Equasens, a leader in digital healthcare solutions, has announced its financial calendar for the 2026 financial year, detailing key dates for revenue and results announcements [1]. Group 1: Financial Calendar - 2025 annual revenue will be reported on February 5, 2026, after market close [2] - 2025 annual results will be released on March 30, 2026, before market opens [2] - 2026 Q1 revenue is scheduled for April 29, 2026, after market close [2] - The Annual General Meeting will take place on June 25, 2026 [2] - 2026 Half-year revenue will be announced on July 30, 2026, after market close [2] - 2026 Half-year results will be available on September 28, 2026, before market opens [2] - 2026 Q3 revenue will be reported on October 29, 2026, after market close [2] Group 2: Company Overview - Equasens Group has been established for over 35 years and currently employs more than 1,400 people across Europe [3] - The Group specializes in digital healthcare solutions that support healthcare professionals in their daily operations, including electronic equipment, digital solutions, and healthcare robotics [4] - Equasens is recognized for its interoperability solutions that enhance coordination among healthcare professionals, improving patient care and the efficiency of the healthcare system [5]

EXOSENS AND THEON INTERNATIONAL ANNOUNCE THE SIGNING OF A CONTRACT WITH OCCAR FOR 100,000 NIGHT-VISION MIKRON BINOCULARS, EMBEDDING 200,000 EXOSENS TUBES FOR A TOTAL VALUE OF APPROXIMATELY €500 MILLION, THE LARGEST FIRM NIGHT-VISION AGREEMENT TO DATE AND MAJOR STEP FOR EUROPEAN DEFENCE CAPABILITIES PRESS RELEASEMÉRIGNAC, FRANCE – 10 DECEMBER 2025 Exosens and Theon International announce the signing of a contract between the THEON/HENSOLDT consortium and OCCAR for 100,000 binocular MIKRON devices, the larges ...

Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a potential new therapeutic approach for difficult-to-treat cancers: No dose limiting toxicity reached to date, enabling recruitment of a third patient cohortGNS561 and MEKi combination demonstrated disease stabilization in all evaluable patients with evidence of tumor shrinkage in a subset of patients ...

Estimated combined annual sales are anticipated to be $56 million with net profit exceeding $10 millionNORTH BERGEN, NJ, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Free Flow, Inc. (OTCQB: FFLO), which is incorporated in the state of Delaware as Free Flow USA, Inc., today announced that it has entered into a Memorandum of Contractual Agreement with a Kuwaiti company to purchase plant and machinery from and set up in Morocco, as a turn-key operation, an “induction steel melting and steel rolling plant” with an annual ...

Press release – Neuilly-sur-Seine, Wednesday, December 10, 2025 – 5.45 pm ARGAN accelerates with the acquisition of three new premium sites leased to FERRERO and PUMA, totalling nearly 100,000 sq.m ARGAN confirms the strengthening of its investment momentum with three new logistics sites scheduled for delivery in the first half of 2026. These buildings are already leased to leading tenants under long-term agreements. ARGAN welcomes two major tenants: FERRERO and PUMA ARGAN has secured two new tenant clients ...

Press Release Paris – December 10, 2025 - EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025)1, and upon the recommendation of the Nominations and Compensation Committee, the Board of Directors has decided to co-opt Tristan Imbert as Independent Director, subject to the vote of EUROAPI Shareholders’ meeting on May 27, 2026. Tristan Imbert will be appointed Chair of the Audit Committee, effective January 01, 20 ...

IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups, although more robust with the full dose Twelve-month data continues to support full dose selection for a future Phase 3 trial Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety d ...